Wednesday, August 13, 2014 10:14:40 PM
All text from the 8/13/14 PR
Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD).
The Company is focusing its resources on advanced clinical studies of fostamatinib in two indications. The fostamatinib programs include a recently initiated Phase 3 study in patients with immune thrombocytopenic purpura (ITP) and its planned Phase 2 study in patients with IgA Nephropathy (IgAN), an autoimmune disease of the kidneys, in Q4 2014. For more information on fostamatinib in IgAN, please visit: http://www.rigel.com/rigel/IgAN.
"Demonstrating clinical benefit in patients with dry eye disease remains a significant challenge for the pharmaceutical industry," said James M. Gower, chairman and chief executive officer of Rigel. "Our energies and resources going forward are committed to supporting fostamatinib in its advanced clinical development," he added.
In addition, Rigel announced it has discontinued its indirect AMPK activator program, R118, due to its side-effect profile in Phase 1 clinical trials. However, the company will continue its direct AMPK activator research program.
"Games are won by players who focus on the playing field -- not by those whose eyes are glued to the scoreboard." - Warren Buffett
Recent RIGL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:01:11 PM
- Rigel to Present at the 2024 Cantor Global Healthcare Conference • PR Newswire (US) • 09/12/2024 12:05:00 PM
- Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML • PR Newswire (US) • 09/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:36:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:33:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 12:30:20 PM
- Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan • PR Newswire (US) • 09/03/2024 12:00:00 PM
- Rigel to Participate in Upcoming September Investor Conferences • PR Newswire (US) • 08/29/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/12/2024 04:15:12 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 09:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:11:12 PM
- Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 08/06/2024 08:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/02/2024 08:53:03 PM
- Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update • PR Newswire (US) • 07/30/2024 12:05:00 PM
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/12/2024 12:05:00 PM
- Rigel Announces Reverse Stock Split • PR Newswire (US) • 06/25/2024 12:00:00 PM
- Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application • PR Newswire (US) • 06/24/2024 08:05:00 PM
- Rigel Announces Five Presentations at the EHA2024 Hybrid Congress • PR Newswire (US) • 06/14/2024 07:05:00 AM
- Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting • PR Newswire (US) • 06/03/2024 12:13:00 PM
- Rigel to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:21:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:20:11 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM